Evidence map›Paper›PMID 23396089›Full record

ArticleBiochemical pharmacology2013

Transcriptome profiling and genome-wide DNA binding define the differential role of fenretinide and all-trans RA in regulating the death and survival of human hepatocellular carcinoma Huh7 cells.

Ying Hu, Hui-Xin Liu, Yuqi He, Yaping Fang, Jianwen Fang, Yu-Jui Yvonne Wan

Open access · greenAbstract readComparative Study
In one paragraph

Article in Biochemical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  3. Retinoic acid and microRNA.Methods in enzymology · 2020
    Article
  4. RARβ acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
    Article
  5. Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2016
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Pathway analysis for drug repositioning based on public database mining.Journal of chemical information and modeling · 2014
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ying HuDepartment of Medical Pathology and Laboratory Medicine, 4645 2nd Ave, Research Building III, University of California, Davis Health Systems, Sacramento, CA 95817, USA. yinghu0821@gmail.com
Hui-Xin Liu
Yuqi He
Yaping Fang
Jianwen Fang
Yu-Jui Yvonne Wan
University of California Davis Medical Center · USUniversity of Kansas · US

Funding

Retinoids Xenobiotic Metabolism and Tumor PromotionR01CA053596 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI WAN, YU-JUI YVONNE · 1996 to 2014
$4.5M
Retinoic Acid, Its Receptors, and the LiverR01DK092100 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI WAN, YU-JUI YVONNE · 2011 to 2014
$1.4M
RETINOIC ACID RECEPTOR ALPHA-FETOPROTEIN AND HEPATOMAR29CA053596 · NCI · LA BIOMED RES INST/ HARBOR UCLA MED CTR · PI WAN, YU-JUI YVONNE · 1991 to 1995
–
NCI NIH HHS CA53596NCI NIH HHS R01 CA053596NIDDK NIH HHS DK092100NIDDK NIH HHS R01 DK092100
6 · The paper itself

Abstract

Fenretinide is significantly more effective in inducing apoptosis in cancer cells than all-trans retinoic acid (ATRA). The current study uses a genome-wide approach to understand the differential role fenretinide and ATRA have in inducing apoptosis in Huh7 cells. Fenretinide and ATRA-induced gene expressions and DNA bindings were profiled using microarray and chromatin immunoprecipitation with anti-RXRα antibody. The data showed that fenretinide was not a strong transcription regulator. Fenretinide only changed the expressions of 1 093 genes, approximately three times less than the number of genes regulated by ATRA (2 811). Biological function annotation demonstrated that both fenretinide and ATRA participated in pathways that determine cell fate and metabolic processes. However, fenretinide specifically induced Fas/TNFα-mediated apoptosis by increasing the expression of pro-apoptotic genes i.e., DEDD2, CASP8, CASP4, and HSPA1A/B; whereas, ATRA induced the expression of BIRC3 and TNFAIP3, which inhibit apoptosis by interacting with TRAF2. In addition, fenretinide inhibited the expression of the genes involved in RAS/RAF/ERK-mediated survival pathway. In contrast, ATRA increased the expression of SOSC2, BRAF, MEK, and ERK genes. Most genes regulated by fenretinide and ATRA were bound by RXRα, suggesting a direct effect. This study revealed that by regulating fewer genes, the effects of fenretinide become more specific and thus has fewer side effects than ATRA. The data also suggested that fenretinide induces apoptosis via death receptor effector and by inhibiting the RAS/RAF/ERK pathway. It provides insight on how retinoid efficacy can be improved and how side effects in cancer therapy can be reduced.

Indexed as

TranscriptomeAntineoplastic AgentsApoptosisCarcinoma, HepatocellularCell Line, TumorCell SurvivalDNAExtracellular Signal-Regulated MAP KinasesFenretinideGene Expression ProfilingGene Expression RegulationHumansLiver Neoplasmsraf Kinasesras ProteinsRetinoid X Receptor alphaAntineoplastic AgentsDNAExtracellular Signal-Regulated MAP KinasesFenretinideraf Kinasesras ProteinsRetinoid X Receptor alphaTretinoin

Identifiers

PMID23396089
PMCPMC3857153
OpenAlexW1974507101

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.